If you’re looking to bolster your portfolio with some blue chip shares, you may want to look at the two listed below.
Here’s why these blue chip ASX 200 shares are highly rated right now:
Goodman Group (ASX: GMG)
The first blue chip ASX 200 share to look at is Goodman Group. It is a leading integrated commercial and industrial property company with a portfolio of warehouses, large scale logistics facilities, and business and office parks.
Management notes that it continues to experience strong demand for its properties, which is being driven by increased intensification of use, long-term supply chain requirements, tight supply in urban infill locations and the quality of its assets.
In addition, the company has $12.7 billion of development work in progress, which is expected to underpin further solid growth over the coming years. Particularly given how the average value of its development work in progress now exceeds $3,700 per square metre, which reflects the prime location, cap rates, and expected growth in rents.
The team at Citi is very positive on Goodman. Its analysts believe the company could outperform its upgraded earnings guidance in FY 2022.
It said: “We now forecast c. 23% EPS growth in FY22 and c. 19% EPS CAGR from FY21-FY24. Our TP increases 5% on higher asset values and higher earnings. GMG remains our top pick in the sector.”
Citi has a buy rating and $29.50 price target on Goodman’s shares.
Healius Ltd (ASX: HLS)
Another blue chip ASX 200 share to look at is Healius. It is one of Australia’s largest pathology and diagnostic imaging providers offering services via a number of brands. These include Dorevitch Pathology, QML Pathology, Laverty Pathology, and Healthcare Imaging Services.
Healius has been growing at a rapid rate over the last couple of financial years thanks to huge demand for COVID testing. And while testing volumes will inevitably decline now, the team at Morgans remain positive on the company and expects its base business to rebound as COVID headwinds ease.
It commented: “We continue to believe HLS is attractively valued and well placed, benefiting from the likely continuance of COVID PCR testing (at some level) and from the inevitable rebound in demand from a backlog in diagnosis and surgery.”
Morgans has an add rating and $5.26 price target on Healius’ shares.
The post 2 blue chip ASX 200 shares to buy according to experts appeared first on The Motley Fool Australia.
Wondering where you should invest $1,000 right now?
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.
*Returns as of January 12th 2022
More reading
- 3 ASX healthcare shares rated as buys by a leading broker
- 2 blue chip ASX 200 shares analysts are urging investors to buy
- Brickworks (ASX:BKW) share price on watch amid 269% first half profit jump
- 2 ASX 200 blue-chip shares to buy this month: experts
- 3 buy-rated blue chip ASX 200 shares according to experts
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/ElJFuWK
Leave a Reply